| Interest and Volume in TapImmune Rising |
 |
 |
| By Staff and Wire Reports | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tuesday, 25 October 2011 06:27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Shares of micro-cap biotech TapImmune, Inc. (OTCBB:TPIV) have seen a steady increase in volume and trading activity in recent weeks. On Friday, the company announced that its Chairman and CEO, Dr. Glynn Wilson, was invited to be a Key Note Speaker at BITeomics' 2nd Annual World Congress on Immunodiseases and Therapy
scheduled to be held in Guangzhou, China, November 18-20, 2011. With the World Health Organization’s recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis are spreading at an alarming rate in Europe, investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases. For some time now, we've been telling readers that the company has been quietly building solid relationships within industry because of the relevance of the TAP technology and we continue to expect positive developments from the firm, particularly with Dr. Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is plenty of evidence now from around the world that shows that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse. Reached for comment, Dr. Glynn Wilson stated: “One of the greatest problems facing our ability to respond to viral pandemics (e.g. bird flu, and bioterror threats of currently unknown origin) is how to be prepared for such possibilities. We envisage that our TAP approach could be widely applied and stockpiled independently so that it could be used alone or in concert with any vaccine antigens that might be available. Our work on smallpox and TB is only the starting point." The Seattle based company’s TAP-based prophylactic vaccine- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology—what he calls "vaccinomics". That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm. "It is a population-based or public health–based approach and, within limits, it has served us well," he says. "But it is has also engendered an antivaccine movement.” Scientific American recently profiled Poland’s work: http://www.scientificamerican.com/article.cfm?id=vaccinomics-personal-vaccine TapImmune announced in August that it is initiating clinical development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer following their recent FDA IND approval for a Phase I HER-2/neu targeted therapeutic vaccine trial in HER-2/neu positive breast cancer patients at the Mayo Clinic. Below is a look at some of Monday's other market movers in healthcare:
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites            |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Newsletter
